Compare SRTA & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRTA | EOLS |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | 353 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 530.4M | 529.1M |
| IPO Year | 2019 | 2018 |
| Metric | SRTA | EOLS |
|---|---|---|
| Price | $5.49 | $8.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $7.81 | ★ $15.50 |
| AVG Volume (30 Days) | 680.8K | ★ 908.6K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 242.86 | 1.23 |
| EPS | ★ N/A | N/A |
| Revenue | $197,141,000.00 | ★ $297,176,000.00 |
| Revenue This Year | $39.27 | $13.27 |
| Revenue Next Year | $8.52 | $17.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $3.95 | $3.86 |
| 52 Week High | $6.50 | $9.31 |
| Indicator | SRTA | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 48.81 |
| Support Level | $5.35 | $7.59 |
| Resistance Level | $5.48 | $8.43 |
| Average True Range (ATR) | 0.18 | 0.34 |
| MACD | -0.00 | -0.14 |
| Stochastic Oscillator | 58.89 | 27.33 |
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.